A Phase 1 Dose-Escalation Study of LY2940680 in Patients With Advanced Cancer
The purpose of this study is to explore the safety and potential efficacy of LY2940680 in advanced basal cell carcinoma. This is targeted therapy against the signaling pathway, Hedgehog, important in basal cell carcinoma growth.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : LY2940680
Phase: Phase 1
Ages Eligible For Study:
- Have histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic. The patient must be, in the judgment of the investigator, an appropriate candidate for experimental therapy. - Have the presence of measurable or nonmeasurable disease - Have adequate organ function, including: - Hematologic: Absolute neutrophil count (ANC) greater than or equal to 1.5 x 109/L, platelets greater than or equal to 100 x 109/L, and hemoglobin greater than or equal to 9 g/dL. Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin until 5 days after the erythrocyte transfusion. - Hepatic: Bilirubin less than or equal to 1.5 times upper limits of normal (ULN), ALT, and aspartate transferase (AST) less than or equal to 2.0 times ULN. If the liver has tumor involvement AST and ALT equaling less than or equal to 5 times ULN are acceptable. - Renal: Serum creatinine less than or equal to 1.5 times ULN. - Have a performance status of less than or equal to 1 on the Eastern Cooperative Oncology Group (ECOG) scale - Have discontinued previous treatments for cancer and recovered from the acute effects of therapy (for example, at least 42 days for mitomycin-C or nitrosoureas, 28 days for other chemotherapy and biologics. At the discretion of the investigator, hormone refractory prostate cancer patients who are stable on gonadotropin-releasing hormone (GnRH) agonist therapy and breast cancer patients who are stable on antiestrogen therapy (for example, an aromatase inhibitor) may continue treatment